Clinical Trials Logo

Clinical Trial Summary

The study was a dose-ranging, 18-week study comparing two doses of HTD1801 (500 mg BID and 1000 mg BID) to placebo in adult subjects with PSC.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03333928
Study type Interventional
Source HighTide Biopharma Pty Ltd
Contact
Status Completed
Phase Phase 2
Start date February 9, 2018
Completion date August 14, 2020

See also
  Status Clinical Trial Phase
Completed NCT05082779 - Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 Phase 1
Completed NCT06037577 - Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects Phase 1
Completed NCT01672853 - Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) Phase 2
Completed NCT02061540 - Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Phase 2
Completed NCT01819766 - Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease N/A
Active, not recruiting NCT01161992 - Genomics of Primary Sclerosing Cholangitis (PSC)
Completed NCT02808312 - Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function Phase 1
Completed NCT02177136 - Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) Phase 2
Completed NCT03766035 - Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
Completed NCT01695174 - A Pilot Study of Xifaxan to Treat Patients With PSC Phase 1
Recruiting NCT06026865 - S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC) N/A